Cost effectiveness analysis of larval therapy for leg ulcers by Soares, Marta O. et al.
RESEARCH
Larval therapy for leg ulcers (VenUS II): randomised
controlled trial
Jo C Dumville,1 Gill Worthy,1 J Martin Bland,1 Nicky Cullum,1 Christopher Dowson,2 Cynthia Iglesias,1
Joanne L Mitchell,3 E Andrea Nelson,4 Marta O Soares,1 David J Torgerson,1 on behalf of the VenUS II team
ABSTRACT
Objective To compare the clinical effectiveness of larval
therapy with a standard debridement technique
(hydrogel) for sloughy or necrotic leg ulcers.
Design Pragmatic, three armed randomised controlled
trial.
Setting Community nurse led services; hospital wards;
hospital outpatient leg ulcer clinics in urban and rural
settings, United Kingdom.
Participants 267 patients with at least one venous or
mixed venous and arterial ulcer with at least 25%
coverage of slough or necrotic tissue, and an ankle
brachial pressure index of 0.6 or more.
Interventions Loose larvae, bagged larvae, and hydrogel.
Main outcome measures The primary outcome was time
to healing of the largest eligible ulcer. Secondary
outcomes were time to debridement, health related
quality of life (SF-12), bacterial load, presence of
meticillin resistant Staphylococcus aureus, adverse
events, and ulcer related pain (visual analogue scale,
from 0 mm for no pain to 150 mm for worst pain
imaginable).
Results Time to healing was not significantly different
between the loose or bagged larvae group and the
hydrogel group (hazard ratio for healing using larvae v
hydrogel 1.13, 95% confidence interval 0.76 to 1.68;
P=0.54). Larval therapy significantly reduced the time to
debridement (2.31, 1.65 to 3.2; P<0.001). Health related
quality of life and change in bacterial load over time were
not significantly different between the groups. 6.7% of
participants had MRSA at baseline. No difference was
found between larval therapy and hydrogel in their ability
to eradicate MRSA by the end of the debridement phase
(75% (9/12) v 50% (3/6); P=0.34), although this
comparison was underpowered. Mean ulcer related pain
scores were higher in either larvae group compared with
hydrogel (mean difference in pain score: loose larvae v
hydrogel 46.74 (95% confidence interval 32.44 to 61.04),
P<0.001; bagged larvae v hydrogel 38.58 (23.46 to
53.70), P<0.001).
Conclusions Larval therapy did not improve the rate of
healing of sloughy or necrotic leg ulcers or reduce
bacterial load compared with hydrogel but did
significantly reduce the time to debridement and increase
ulcer pain.
Trial registration Current Controlled Trials
ISRCTN55114812 and National Research Register
N0484123692.
INTRODUCTION
Larval therapy is used to promotewound debridement
and has also been suggested to stimulate wound
healing,1 reduce bacterial load,2 and eradicate meticil-
lin resistant Staphylococcus aureus.3 However, the treat-
ment has been evaluated in just one published
randomised controlled trial, which included only 12
patients with venous leg ulcers and reported debride-
ment and not healing.4 We evaluated the effectiveness
of larval therapy compared with a standard debride-
ment treatment (hydrogel) in the treatment of leg
ulcers, The economic evaluation is reported in the
accompanying paper.5
METHODS
This was a pragmatic multicentre, randomised, open
trial with equal randomisation, carried out in 22 cen-
tres in the United Kingdom from July 2004 to May
2007. Eligible participants had venous or mixed
venous and arterial leg ulcers with at least 25% cover-
age by slough or necrotic tissue. We considered ulcers
with an area of 5 cm2 or less as eligible if theywere non-
healing (no change in area over preceding month). If a
patient hadmultiple ulcerswe chose the largest eligible
ulcer as the reference lesion.
Participantswere randomised to receive loose larvae
(Zoobiotic; Bridgend, Wales), bagged larvae (Bio-
monde; Barsbüttel, Germany), or hydrogel (Purilon;
Coloplast, Denmark). Randomisation was done by
telephone, using permuted blocks with stratification
by trial centre and ulcer area (≤5 cm2 or >5 cm2).
Interventions
Nurseswere encouraged to consider all participants for
compression and to use four layer bandaging unless
contraindicated by ankle brachial pressure index or
patient tolerance.
We used sterile Lucilia sericata larvae, which were left
in situ for three or four days; during which participants
could not receive compression bandaging. Participants
in the control group received hydrogel covered with a
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knitted viscose dressing and compression depending on
the ankle brachial pressure index and patient tolerance.
Allocated treatment was applied in the debridement
phase. In the phase after debridement, participants
received a standard knitted viscose dressing with or
without compression. The maximum length of fol-
low-up was 12 months.
Outcome measurements
The primary outcome was time to healing of the refer-
ence ulcer, defined as complete epithelial cover in the
absence of a scab, which was assessed by the nurse and
independently corroborated by another nurse one
week later. Nurses took photographs of the ulcer
weekly for six months and then monthly. These were
assessed for healing status by two independent asses-
sors, masked to treatment.
Secondary outcomes were time to debridement,
health related quality of life, bacterial load and
MRSA, adverse events, andulcer relatedpain.Debride-
ment was defined as a cosmetically clean wound.
Nurses recorded the date a wound had debrided, and
blinded assessors checked photographs to judge
whether complete debridement had occurred. We
used the SF-126 to measure participants’ perceptions
of health related quality of life at baseline and at three,
six, nine, and 12 months.
Swabs were taken at baseline, after removal of each
trial debridement treatment during the first month (if
the ulcer debrided within onemonth then weekly until
onemonth), and thenmonthly until healing or the trial
ended. Laboratory analysis, blinded to treatment,
measured total bacterial load and MRSA.
We classed adverse events as serious (for example,
life threatening event, admission to hospital) or non-
serious. The seriousness of other events (for example,
infection and deterioration of the wound) was judged
by the treating nurse. Health professionals indicated
whether or not they believed the event was related to
trial treatment.
Participants recordedulcer related pain over the past
24 hours on a visual analogue scale at baseline and first
removal of the trial treatment, from no pain (0 mm) to
worst pain imaginable (150 mm).
Statistical analysis
Wecompared time to debridement and time to healing
between the groups using a log rank test. These treat-
ment effects were explored in a Cox proportional
hazards model including randomisation stratification
factors (centre, baseline ulcer area) as well as prognos-
tic variables (duration of ulcer and ulcer type: ankle
brachial pressure index ≥0.8 and high compression or
lower or no compression; ankle brachial pressure
index 0.6-0.8). We decided a priori that if there was
no evidence of a difference between loose and bagged
larvae groups we would present the hazard ratios and
95% confidence intervals for larvae groups combined
compared with hydrogel.
For each participant we calculated the physical and
mental component scoresof theSF-12.The standardised
areas under the curve7 were reported for the larvae and
hydrogel groups and compared using a Wilcoxon rank
sum test. Values were compared with those of age spe-
cific norms, available for the United States.8
Data on bacterial load were log transformed. We
used a repeated measures regression model to com-
pare changes in bacterial load over time between the
groups. Time of swabbing was a continuous measure
and we included a quadratic term to test if the effects of
time were non-linear. We considered treatment, time,
baseline ulcer area, ulcer type, and duration of ulcer as
fixed effects and participants as random effects. The
interaction between treatment and time was also
assessed. We analysed bacterial load to the end of the
trial and to the end of the debridement phase.
We used Fisher’s exact test to compare the proportion
of participants (positive for MRSA at baseline) with
MRSA eradicated by the end of the debridement phase
between larvae and hydrogel groups. This was repeated
for the proportion of participants who were negative for
MRSA at baseline but who tested positive later.
Using a negative binomial model and adjusting for
the same covariates as the primary analyses we com-
pared the numbers of adverse events in each partici-
pant between treatment groups. We also compared
groups for ulcer related pain during the 24 hours
before the first removal of the debridement treatment
using linear regression and adjusting for baseline pain
score, ulcer area, duration of ulcer, and ulcer type.
RESULTS
Overall, 267 of 1712 (15.6%) people with leg ulcers
were randomised: 94 to loose larvae, 86 to bagged lar-
vae, and 87 to hydrogel. See bmj.com for characteris-
tics of the participants.
Time to healing did not differ between the groups (log
rank test 1.00, df=2, P=0.62). In the adjusted analysis, as
healing rates didnotdiffer between the loose andbagged
larvae arms (χ2 0.19, df=1, P=0.66), results are presented
for the larvae arms combined compared with hydrogel.
The median time to healing in the larvae group was
236 days (95% confidence interval 147 to 292) and in
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the hydrogel group was 245 days (166 to not estimable).
The figure shows the survival curve for time to healing.
The hazard ratio from the adjusted analysis for lar-
vae comparedwith hydrogelwas 1.13 (95%confidence
interval 0.76 to 1.68, P=0.54), indicating a slightly
increased likelihood of healing in the larvae group,
although this was not statistically significant.
Time to debridement differed significantly between
the three groups (25.38, df=2, log rank test P<0.001).
Themedian time to debridement with loose larvaewas
shorter (14 days, 95% confidence interval 10 to 17)
than with bagged larvae (28 days, 13 to 55) and with
hydrogel (72 days, 56 to 131). When loose and bagged
larvae were compared in the adjusted analysis, how-
ever, the difference in time to debridement was not
significant (χ2 1.52, df=1, P=0.22).
The rate of debridement at any time in either larvae
groups was about twice that of the hydrogel group
(hazard ratio for combined larvae group compared with
hydrogel 2.31, 95% confidence interval 1.65 to 3.24,
P<0.001).
The mean baseline physical component score for the
combined larvae group was 33.3 (SD 11.4) and for the
hydrogel group was 35.9 (SD 11.5). These values were
low compared with the 37.9 (SD 11.16) for norm based
scores of people aged 75 and over in the US. The mean
baseline mental component score for the combined lar-
vae groupwas 46.9 (SD12.3) and for thehydrogel group
was 47.2 (SD 11.0), compared with 50.4 (11.66) for the
general US population. The physical component sum-
mary scores did not differ between the groups (median
area under the curve: 0.4 for combined larvae, −0.5 for
hydrogel, P=0.25), indicating no evidence of a difference
between them (see bmj.com). The result for the mental
component summary score was −0.8 for combined lar-
vae, −0.7 for hydrogel, P=0.95 (see bmj.com).
The average log bacterial count at baseline was 6.5
(about 3.1×106 copies/ml) and was similar across the
groups. Data from swabs showed no evidence of a dif-
ference in bacterial load over time between the com-
bined larvae and the hydrogel groups (difference in
means (larvae minus hydrogel) −0.06, 95% confidence
interval −0.24 to 0.12, P=0.75).
The prevalence of MRSA at baseline was low, with
only 6.7% of participants (18/267) having a positive
swab at baseline: seven participants allocated to loose
larvae, five allocated to bagged larvae, and six allo-
cated to hydrogel.Of these,MRSAwas eradicateddur-
ing the debridement phase in, respectively, 57.1%
(4/7), 100% (5/5), and 50% (3/6). There was no evi-
dence of a difference between the combined larvae
and the hydrogel groups (75% (9/12) v 50% (3/6);
P=0.34). The number of participants who were nega-
tive for MRSA at baseline but positive at one or more
follow-up assessments did not differ between the com-
bined larvae and the hydrogel groups (7.1% (12/168) v
2.5% (2/81); Fisher’s exact test P=0.16).
In total, 131 participants had 340 adverse events. Of
these, 13.8% were classed as serious, corresponding to
14.6% events with loose larvae, 13.5%with bagged lar-
vae, and 13.5% with hydrogel.
The mean ulcer related pain scores with larvae were
about double those with hydrogel (see bmj.com). After
adjustment, significantly more pain was experienced
by participants in both larvae groups (P<0.001) than
in the hydrogel group.
DISCUSSION
A phase of treatment with loose or bagged larvae did
not reduce time to healing of leg ulcers compared with
hydrogel.We also found no evidence of a difference in
health related quality of life or bacterial load.Our find-
ings do indicate that larvae are amore effective debrid-
ing agent than hydrogel.
This is the first report of pain associated with larval
therapy, with a control group for comparison. Pain
reported in the 24 hours before removal of the first
larvae treatment was considered related to the proce-
dure and therefore transient and did not seem to
impact on the health related quality of life measure-
ments made at three monthly intervals.
The low rate of MRSA identified in these mainly
community dwelling patients is welcomed and con-
trasts with previous reports.9 10 We also showed that
MRSA can be eradicated from leg ulcers irrespective
of treatment type. One limitation was that we only
investigated an association between larval therapy
and total bacterial load. Beyond identification of
MRSA we did not investigate other bacterial flora.
We investigated the effect of larval therapy on
wound healing and used blinded outcome assessment
to protect against observer bias. Although trial evi-
dence is limited, there are several non-randomised
controlled trials that led to the promotion of larval ther-
apy as a clinically effective treatment,11-15 with “effec-
tive” variously defined.
Finally, we did not reach our initial sample size. The
reasons may be complex. Anecdotally, nurses thought
there were fewer patients with leg ulcer than pre-
viously, attributing this to an increased use of compres-
sion bandaging. Secondly, fewer ulcers than we
originally anticipated were sloughy.
We found no evidence to recommend the routine
use of larval therapy on sloughy leg ulcers to speed
up healing or reduce bacterial load. If debridement in
itself is a goal of treatment, then larval therapy should
WHAT IS ALREADY KNOWN ON THIS TOPIC
Larvae are increasingly used to treat leg ulcers and are thought to stimulate healing, reduce
bacterial load, and eradicate MRSA
Clinical evidence to support larval therapy comes from a small randomised controlled trial
that did not follow patients to healing
WHAT THIS STUDY ADDS
Larval therapy significantly reduced the time to debridement of sloughy or necrotic leg ulcers
compared with hydrogel
Larval therapy did not increase healing rates nor reduce bacterial load and was associated
with significantly more ulcer related pain in the 24 hours before removal of the first treatment
than with hydrogel
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be considered; however, it is associated with signifi-
cantly more pain than hydrogel.
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ABSTRACT
Objective To assess the cost effectiveness of larval
therapy compared with hydrogel in the management of
leg ulcers.
DesignCost effectiveness and cost utility analyses carried
out alongside a pragmaticmulticentre, randomised, open
trial with equal randomisation.
Population Intention to treat population comprising 267
patientswith a venous ormixed venous and arterial ulcers
with at least 25% coverage of slough or necrotic tissue.
Interventions Patients were randomly allocated to
debridement with bagged larvae, loose larvae, or
hydrogel.
Main outcome measure The time horizon was 12 months
and costs were estimated from the UK National Health
Service perspective. Cost effectiveness outcomes are
expressed in terms of incremental costs per ulcer-free day
(cost effectiveness analysis) and incremental costs per
quality adjusted life years (cost utility analysis).
Results The larvae arms were pooled for the main
analysis. Treatment with larval therapy cost, on average,
£96.70 (€109.61; $140.57) more per participant per year
(95% confidence interval −£491.9 to £685.8) than
treatment with hydrogel. Participants treated with larval
therapy healed, on average, 2.42 days before those in the
hydrogel arm (95% confidence interval −0.95 to 31.
91 days) and had a slightly better health related quality of
life, as the annual difference in QALYs was 0.011 (95%
confidence interval −0.067 to 0.071). However, none of
these differences was statistically significant. The
incremental cost effectiveness ratio for the base case
analysis was estimated at £8826 per QALY gained and
£40 per ulcer-free day. Considerable uncertainty
surrounds the outcome estimates.
Conclusions Debridement of sloughy or necrotic leg
ulcers with larval therapy is likely to produce similar
health benefits and have similar costs to treatment with
hydrogel.
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Trial registration Current Controlled Trials
ISRCTN55114812 and National Research Register
N0484123692.
INTRODUCTION
A common belief is that necrotic tissue and slough
might interfere with wound healing, although no
strong evidence supports this theory.1-3 Larval therapy
has been proposed as a potentially effective and cost
effective method for debridement and is thought to
promote healing. Compared with hydrogel (standard
treatment), each application of larvae is expensive (£58
for loose larvae, £98.79 for bagged larvae, £1.55 for
hydrogel) and more consultations with nurses are
likely to be required up to debridement.
We carried out an economic evaluation alongside a
large multicentre randomised controlled trial to investi-
gate the cost effectiveness of larval therapy compared
with hydrogel in patients with sloughy or necrotic
venous and mixed venous and arterial leg ulcers. The
clinical results are published in an accompanying
paper.4
METHODS
Patients with venous or mixed venous and arterial leg
ulcers were eligible for recruitment if one of the ulcers
had at least 25% surface coveragewith slough or necro-
tic tissue. Participants were randomised to hydrogel,
loose larvae, or bagged larvae. Larvae were left in situ
for three or four days, during which time the patients
received nursing care for wound management. On
removal of the larvae the treating nurse assessed
whether a further application was required. We refer
to the applicationof treatment until debridement or the
discontinuation of treatment as the debridement
phase. Participants did not receive compression during
larval therapy. This trial design therefore relates to the
pragmatic question of whether the benefits of larval
therapyoutweigh the disbenefits of goingwithout com-
pression during larval therapy.
Economic analysis
We used patient level data collected within a rando-
mised controlled trial (VenUS II). Intention to treat
analyses compared incremental costs with incremental
ulcer-free days (cost effectiveness analysis) and incre-
mental quality adjusted life years (cost utility analysis).
Time to healing was the outcome measure in the cost
effectiveness analysis.
The perspective for the economic evaluations was
that of the NHS and Personal Social Services.5 The
year of pricing was 2006. The time horizon was
12 months after recruitment, and consequently we dis-
counted neither costs nor health benefits.
As decided a priori in the clinical analysis, if evi-
dence of a statistically non-significant difference in
debridement time between loose and bagged larvae
was found, data from both groups would be pooled.
The incremental economic analysis therefore consid-
ered the combined group.
Resource use and unit costs
We collected data on use of resources from nurse com-
pleted and participant completed questionnaires.
Information on numbers of loose and bagged larvae
and hydrogel applications was recorded by nurses at
each consultation. Unit costs for debriding agents
were obtained from the British National Formulary and
larvae suppliers.
Data on contacts with nurses and doctors were avail-
able from both nurses and participants. Nurse reported
data were collected for only the reference ulcer, and par-
ticipants’ reported data for all ulcers and ulcer related
conditions. Participants with several ulcers continued
recording healthcare resource use irrespective of the
healing status of the reference ulcer, and these data
were used in the base case analysis. Hospital consulta-
tions were costed on an outpatient basis (see bmj.com).
The type of compression therapy was recorded at
each visit and the costs estimated as the arithmetical
average cost for commercially available systems.4
Other dressings and treatments were assumed to be
used similarly across treatment arms.6
Health outcomes
Health benefit was measured in terms of ulcer-free
days and quality adjusted life years (QALYs). Time to
healing of the reference ulcer was recorded by nurses
and independently ascertained from photographs by
blinded investigators.4 Health related quality of life
data (EQ-5D7) were collected at baseline and at three,
six, nine, and 12months. Utility scores were calculated
using an independent predefined algorithm.8 Thus
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time lived in perfect health has a weight of 1, which
decreases as health becomes impaired. Quarterly
QALYs were calculated by applying individual’s
utility weights to survival time using the area under
the curve approach,9 10 which was defined by linearly
interpolating the utility scores measured over time.
Statistical analysis
Estimates of expected cost and health benefit were
reported for larval therapy (pooled data) and hydrogel.
For completeness we present descriptive measures of
costs and health benefits for each of the three trial arms.
We used inverse probability weighting11-13 to esti-
mate the mean time to healing, costs, and QALYs,
accounting for the censored nature of these data.14
The weights were evaluated as the inverse of the
Kaplan Meier estimator of censoring probability. For
QALYs and cost estimation, we partitioned the time
horizon in quarterly intervals through the weighted
regression mean cost, and QALYs were estimated
within each interval and then summed across intervals
to estimate mean total costs and QALYs.
Linear regression was used to adjust the estimates for
type of ulcer, duration of ulcer (logarithmic), ulcer area
(logarithmic), and centre (aggregating centreswith fewer
than 10 participants). We included baseline EQ-5D
scores as a covariate in the estimation of QALYs.9
We calculated 95% confidence intervals for differen-
tial costs and effectiveness using non-parametric boot-
strap estimates (bias corrected).15 For each bootstrap
resample we obtained adjusted estimates of expected
total costs and effectiveness measures.
A treatment strategy can be considered cost effective
only if the decision maker’s willingness to pay for an
additional unit of health benefit is equal to or greater
than the incremental cost effectiveness ratio.Neverthe-
less, this cost effectiveness decision is uncertain
because expected costs and effectiveness are estimated
under conditions of uncertainty. We explored this
uncertainty using cost effectiveness planes and accept-
ability curves.16
RESULTS
Overall, 267 people were recruited: 94 were allocated
to loose larvae, 86 to bagged larvae, and 87 to hydro-
gel. Randomised treatments were administered to 88
(94%), 82 (95%), and 78 (90%) participants, respec-
tively. Mean follow-up time was 171 days (167 days
for loose larvae group, 170 days for bagged larvae
group, and 175 days for hydrogel group).
Resource use
Participants allocated to larval therapy received their
first application about three days later than those allo-
cated to hydrogel, owing to the need to order the larvae
(see bmj.com). Participants in either larval therapy arm
received on average 1.45 applications before the treat-
ment was discontinued or data were censored com-
pared with on average 9.2 applications in the
hydrogel arm. Nineteen participants never received
the allocated treatment. The duration of trial treatment
was, on average, 30 days longer in the hydrogel arm
than in the larvae arms (43 v 12 days).
The average numbers of total consultations with
healthcare professionals during follow-up were similar
across groups (59 for loose larvae, 56 for bagged larvae,
and 61 for hydrogel), with most visits being ulcer
related (81% overall, 47/58; see bmj.com). Nurse con-
sultations accounted for 71% of the total number of
healthcare consultations (42/59).
The use of high and low compression bandaging was
similar across the three arms (see bmj.com)—compres-
sion was received by 87% of participants (82/94) in the
loose larvae arm, 91% (78/86) in the bagged larvae arm,
and 93% (81/87) in the hydrogel arm.
Total costs
The average estimated cost of the trial treatment per
application was: loose larvae £71.70 (SD £13.40),
bagged larvae £111.90 (SD 33.6), and hydrogel £1.50
(SD 0).
The mean total unadjusted costs incurred by partici-
pants was £1833 (SD £1978) for loose larvae, £1696 (SD
£1948) for bagged larvae, and £1596 (SD £1861) for
hydrogel. The cost of nurse and hospital visits was the
major driver of total costs; representing 85% for loose
larvae, 77% for bagged larvae, and82%of the total unad-
justed costs for hydrogel.Half of themean incurred costs
observed during the trial (available case analysis) were
incurred during the first threemonths of follow-up in all
arms. The analysis adjusted for censoring, baseline
imbalances, and stratification variables shows that treat-
mentwith larvae costs, on average, £96.70more per par-
ticipant per year (95% confidence interval −£491.90 to
£685.80) than treatment with hydrogel (see bmj.com).
This difference was not statistically significant.
Health outcomes
On average and after adjustment for baseline imbal-
ances and stratification variables, participants treated
with larval therapy healed 2.42 days before those in the
hydrogel arm. However, this difference was not statis-
tically significant (95%confidence interval−40.95days
to 31.91 days; see bmj.com).
The adjusted results show that patients in the larval
therapy arms had, on average, a slightly better quality
of life than those in the hydrogel arm (annual differ-
ence in QALYs 0.011, 95% confidence interval
−0.067 to 0.071; see bmj.com).
Cost effectiveness and associated uncertainty
The incremental cost effectiveness ratio associated
with use of larval therapy was estimated at £8826 per
QALY gained and £40 per ulcer-free day. The point
estimates of cost and effect differences were small rela-
tive to their standard error, indicating considerable
uncertainty associatedwith the decision to adopt larval
therapy (see bmj.com).
Despite the point estimate for the incremental cost-
utility ratio (£8826) being below the £30000 per
QALY that is generally accepted as being a “threshold”
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of cost effectiveness by the National Institute for Health
and Clinical Excellence, considerable uncertainty sur-
rounds this estimate. The cost effectiveness acceptability
curve (figure), plotted for a range of willingness to pay
thresholds (cost per QALY), suggests that in the base
case analysis theprobability of larvaebeing cost effective
in relation to hydrogel never exceeds 63%.
DISCUSSION
Our base case analysis indicates that, compared with
hydrogel, larval therapy confers a small health benefit
for people with leg ulcers, as measured byQALYs and
time to healing, at a minor additional cost to the NHS.
The incremental cost effectiveness ratio for the base
case analysis was estimated at £8826 perQALYgained
and £40 per ulcer-free day. Yet our non-parametric
confidence intervals indicated a high level of uncer-
tainty associated with the differential cost, effective-
ness, and cost effectiveness of larval therapy
compared with hydrogel. The spread of points on the
cost effectiveness plane (see bmj.com) was almost uni-
form over the four quadrants, suggesting that the nat-
ure of the uncertainty associatedwith our results is such
that larval therapy is likely to be as costly and as effec-
tive as hydrogel.
Debridement and health related quality of life
The impact of larval therapy on health related quality
of life is unclear. As a consequence of the high levels of
morbidity in patients with leg ulcers, it could be argued
that generic health related quality of life instruments
might not capture the benefits of ulcer treatments. Pre-
vious work, however, showed that both the SF-12 and
EQ-5D are sensitive to, and thus able to measure,
changes in healing status of patients with venous leg
ulcer.17 Although debridement was more rapid with
larval therapy, measurement of its effect on health
related quality of life might have been hindered by
some factors. Health related quality of life data were
collected at quarterly intervals whereas the median
time for debridement in the larvae groupswas between
14 and 28 days10; this time gap might have interfered
with the instrument’s ability to capture any small
changes in health related quality of life.
Data characteristics
An important characteristic of our dataset was the high
proportion of censored data. Heavy censoring is not
unusual in studies on patients with high morbidity
and frequent transfers between hospital and commu-
nity healthcare settings. Baseline health related quality
of life scores indicated a higher than average level of
morbidity among the population under evaluation,
which may account for more than 40% of participants
failing to complete the health related quality of life
questionnaires at the final follow-up. Inverse probabil-
ity weighting methods were used to account for this
important feature of our data in the estimation of
mean health benefits and costs.
In this cost effectiveness analysis, healing was the
event of interest; individuals lost to follow-upwere cen-
sored as were those who died. As healing cannot occur
after death, censoring in such cases may conflict with
the assumption of non-informative censoring, com-
mon to most methods of survival analysis.
Strengths and weaknesses
This is the first full economic evaluation alongside a
randomised controlled trial evaluating the value for
money of a single phase of larval therapy compared
with hydrogel for the debridement and healing of
sloughy or necrotic venous or mixed aetiology leg
ulcers.
While our findings have strong external validity for
the UKNHS, the applicability of these results to other
settings worldwide may require further consideration.
Variations on the use of debriding agents may have an
impact on the cost effectiveness of these treatments.
Conclusions
One phase of larval therapy used until initial debride-
ment of leg ulcers is likely to produce a similar level of
health benefit at a similar cost to hydrogel. It could be
argued that decision makers should be indifferent
when recommending these two therapies or that the
decision should be driven by the goal of treatment.
The choice of treatment may then be driven by
patients’ wishes and experiences of pain with larvae.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Larval therapy, a traditional approach to wound
management, is widely used on leg ulcers
Only one randomised trial with 12 participants has been
carried out previously and did not measure ulcer healing or
do a full cost effectiveness analysis
WHAT THIS STUDY ADDS
Larval therapy for the debridement of sloughy or necrotic
venous or mixed aetiology leg ulcers is likely to have similar
cost effectiveness to hydrogel
Healthcare decision makers should generally be indifferent
when recommending between these two treatments
The choice of treatment may then be driven by patients’
wishes and experiences of pain with larvae
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Four layerbandagecomparedwith short stretchbandage for
venous leg ulcers: systematic review and meta-analysis of
randomised controlled trials with data from individual
patients
Susan O’Meara,1 Jayne Tierney,2 Nicky Cullum,1 J Martin Bland,1 Peter J Franks,3,4 Trevor Mole,5 Mark Scriven6
ABSTRACT
Objective To compare the effectiveness of two types of
compression treatment (four layer bandage and short
stretch bandage) in people with venous leg ulceration.
Design Systematic review and meta-analysis of patient
level data.
Data sources Electronic databases (the Cochrane Central
Register of Controlled Trials, the CochraneWounds Group
Specialised Register, Medline, Embase, CINAHL, and
National Research Register) and reference lists of
retrieved articles searched to identify relevant trials and
primary investigators. Primary investigators of eligible
trials were invited to contribute raw data for re-analysis.
Review methods Randomised controlled trials of four
layer bandage compared with short stretch bandage in
people with venous leg ulceration were eligible for
inclusion. The primary outcome for themeta-analysis was
time to healing. Cox proportional hazards models were
run to compare the methods in terms of time to healing
with adjustment for independent predictors of healing.
Secondary outcomes included incidence and number of
adverse events per patient.
Results Seven eligible trials were identified (887
patients), and patient level data were retrieved for five
(797 patients, 90% of known randomised patients). The
four layer bandage was associated with significantly
shorter time to healing: hazard ratio (95% confidence
interval) from multifactorial model based on five trials
was 1.31 (1.09 to 1.58), P=0.005. Larger ulcer area at
baseline, more chronic ulceration, and previous
ulceration were all independent predictors of delayed
healing. Data from two trials showed no evidence of a
difference in adverse event profiles between the two
bandage types.
Conclusions Venous leg ulcers in patients treated with
four layer bandages heal faster, on average, than those of
people treated with the short stretch bandage. Benefits
were consistent across patients with differing prognostic
profiles.
INTRODUCTION
Compression bandaging is thought to assist healing of
venous leg ulcers by reducing distension in the leg
veins and accelerating venous blood flow.1 A previous
systematic review of published trial level data con-
cluded that compression was more effective in healing
venous leg ulcers than no compression, multi-layered
systems were more effective than single layer systems,
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and high compression was more effective than low
compression, but no clear differences in effectiveness
were detected between different types of high
compression.2
The four layer bandage (an elastic system), which is
the standard compression treatment in the United
Kingdom, comprises orthopaedic wool, crepe ban-
dage, elastic bandage, and a final cohesive retaining
layer. All layers are applied from toes to knee and nor-
mally require weekly renewal but can be changed
more often if necessary. The short stretch system, stan-
dard treatment inmainlandEurope andAustralia, is an
inelastic bandage. An orthopaedic wool layer is cov-
ered by the bandage applied at full stretch to create a
rigid casing around the limb that generates resistance
against calf muscles and other tissues with reapplica-
tion every few days.1 The short stretch bandage has
the advantage of being washable and reusable.3 The
four layer bandage is designed to be discarded after a
single use.
We carried out a systematic review and meta-analy-
sis based on individual patient data to compare the
effects of four layer bandage and short stretch bandage
on time to healing of venous leg ulcers, taking account
of prognostic factors.
METHODS
Randomised controlled trials of four layer bandage
compared with short stretch bandage for the treatment
of venous leg ulcers were eligible for inclusion. See
bmj.com for databases searched. All searches were
updated in March 2008. We examined the reference
lists of eligible trials and asked trialists for details of
other trials. Two reviewers (SO’M and NC) indepen-
dently decided on study selection with disagreements
resolved by discussion.
Data collection and end points
We established contact with authors of all relevant
trials. We asked trialists to provide anonymised base-
line and outcome data for each randomised patient,
including those excluded from their own analyses, to
maintain randomised groups and to provide as com-
plete a dataset as possible for the meta-analysis. See
bmj.com.
Time tohealingwasdefined as the time from thedate
of randomisation to the date of healing, with healing
defined as complete epithelialisation of the reference
wound. Wounds were examined at least once a week
in all trials. Data for patients with ulcers not healing
within the trial period were censored on the date of
last follow-up.
Statistical analysis
The patient was both the sampling unit and the unit of
analysis.4 In cases where patients hadmultiple wounds
included in the trial, we selected the largest for inclu-
sion in the meta-analysis. Analyses were undertaken
on an intention to treat basis.
The primary outcome was time to healing. We per-
formed a preliminary (unadjusted) analysis by generat-
ing non-stratified Kaplan-Meier survival curves for
both treatment groups. The dependent variable was
time to healing in days, the event was a healed ulcer,
and the factor was bandage type.
Next, we generated a Cox proportional hazards
model with time to healing in days as the dependent
variable, healing as the event, and bandage type as a
covariate. This preliminary model did not include
adjustment for baseline characteristics. The main pre-
planned analysis entailed a Cox proportional hazards
model with additional covariates of sex, age, primary
or recurrent ulceration, ulcer duration, ulcer area,
ulcer diameter, appearance of wound bed, ulcer infec-
tion, ankle brachial pressure index, ankle circumfer-
ence, ankle mobility, patient’s mobility, and history
of comorbidities—for example, deep vein thrombosis.
We then used a backward elimination method to gen-
erate hazard ratio estimates of treatment effect. The
model was extended to include tests of statistical inter-
action between type of bandage and baseline charac-
teristics. To take account of any differences in healing
rate between study centres, we entered centres into the
model as strata; this also automatically included trials
as strata.
To generate a forest plot showing the relative contri-
bution of each trial to the meta-analysis, we derived
individual trial estimates from the individual patient
data using Cox regression with covariate adjustment
as per the final model. These hazard ratio estimates
were then combined to provide a visual display of the
overall estimate of treatment effect. This secondary
analysis allowed assessment of heterogeneity between
trials, defined with the χ2 test (cut off <10% for signifi-
cance) and the I2 statistic (threshold of >50%).
Adverse events were defined as any adverse event or
those considered by the original investigators to be
related to the bandage. For each of these, we assessed
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the effect of bandage type on the incidence of adverse
events using the odds ratio. We compared the number
of adverse events per patient for the two bandage sys-
tems using a weighted mean difference.
RESULTS
The search strategy retrieved 128 records of possible
relevance. Of these, six trials were eligible for inclu-
sion.w1-w6 We could not retrieve data for one trial
because all records had been destroyed.w2
We identified an additional eligible unpublished
trial but data for this trial were no longer available. See
bmj.com for details of all eligible trials and patients’
characteristics for the five trials with available indivi-
dual patient data (89.8% of known randomised
patients). Prognostic factors were balanced across
treatment groups for the meta-analysis dataset.
All five trials used adequate methods of randomisa-
tion and allocation concealment and all defined heal-
ing as complete epithelial cover of the ulcer site with
non-blinded assessment by clinicians.w3-w6
The characteristics of patients included in this meta-
analysis seemed generally representative and there
was an adequate spread of data for prognostic baseline
variables such as ulcer area and ulcer duration. Most
patients were ambulant. Reported follow-up periods
for trials ranged from three to 12 months. The overall
median follow-up of patients who did not heal during
the trial period was around 13 weeks.
Time to healing
Preliminary analysis
The median time to healing estimated from unstrati-
fied Kaplan-Meier survival analysis of all available
patients (n=797) was 90 days for four layer bandage
and 99 days for the short stretch bandage.
Main analysis
An initialCoxproportional hazardsmodel basedon all
five trials (797 patients, 20/797 cases dropped) was
generated with time to healing (days) as the dependent
variable, healing as the event, study centres as strata,
and bandage type as the only covariate. The result of
this unadjusted analysis indicated no significant differ-
ence between bandage types: hazard ratio 1.15, 95%
confidence interval 0.97 to 1.37; P=0.11.
The nextCoxmodel (five trials, 797 patients, 75/797
cases dropped) included all significant covariates iden-
tified during univariate analyses. After backward elim-
ination, the final model contained only those making a
significant contribution: type of bandage, ulcer dura-
tion, and ulcer area (table). The hazard ratio for ban-
dage type was 1.31 (1.09 to 1.58; P=0.005), suggesting
an increased probability of healing of around 30%with
the four layer bandage. There was significant evidence
that larger ulcers (P<0.001) and ulcers of longer dura-
tion (P<0.001) predicted longer time to healing inde-
pendently of one another and of treatment. The chance
of healing was reduced by a factor of 0.44 for each 10-
fold increase in area. We categorised baseline ulcer
duration into ≤1month, >1-6 months, >6-12 months,
and >12 months. The data suggest that the hazard of
healing was reduced for each step up to a longer dura-
tion interval. We found no significant interactions
between bandage and baseline ulcer area and bandage
and ulcer duration. The figure illustrates the relative
contribution of each trial to the meta-analysis (hetero-
geneity between trials: χ2 test P=0.11, I2=47.7%).
We re-ran the analysis on a subset of four trials (747
patients, 83/747 dropped) for which additional covari-
ates were available (primary or recurrent ulceration
and patient’s mobility). The estimated hazard ratio
for type of bandage was similar to the model based
on five trials: 1.29, 1.06 to 1.57; P=0.011. The model
suggested that larger ulcers (P<0.001), ulcers of longer
duration (P<0.001), and previous ulceration (P<0.005)
were independent predictors of longer time to healing.
Adverse events
Two trials provided data on adverse events.w1 w6 For
incidence of any type of adverse event, the pooled
odds ratio (fixed effect) was 1.15 (95%confidence inter-
val 0.81 to 1.62; P=0.43), providing no evidence of a
difference between bandage types. The two trials dif-
fered in their definitions of bandage related adverse
events. One trial coded events such as maceration,
allergic reaction, eczema of periulcer skin, and infec-
tion as bandage related.w1 Another trial, which com-
pared primary dressings as well as bandages,
attributed these events to the former.w6 In view of this
difference, we did not pool data. We estimated odds
ratios for each trial individually and neither showed a
Final model based on five trials. Regression coefficients (β) with standard errors (SE) and hazard ratios (HR) with 95%
confidence intervals
Variable β (SE) HR (95% CI ) P value
Bandage 0.27 (0.10) 1.31 (1.09 to 1.58) 0.005
Duration category (months):
Overall — — <0.001
1.01-6.0 v 0-1 −0.12 (0.11) 0.89 (0.71 to 1.11) 0.293
6.01-12.0 v 0-1 −0.53 (0.19) 0.59 (0.40 to 0.85) 0.005
>12 v 0-1 −1.07 (0.19) 0.35 (0.24 to 0.50) <0.001
Loge ulcer area −0.36 (0.05) 0.70 (0.64 to 0.77) <0.001
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significant difference between groups: 1.41 (0.94 to
2.11)w1 and 0.78 (0.30 to 2.04).w6
Analysis of the number of all types of adverse event
per patient did not show a difference between the two
bandage systems. See bmj.com.
DISCUSSION
When compared with short stretch bandage, the four
layer bandage increases the chance of healing by
around 30% when independent prognostic factors are
taken into account. The benefit of four layer bandaging
is consistent across patients with differing prognostic
profiles. The largest trial incorporated an economic
analysis and concluded that the four layer system had
lower costs with greater health benefits.w1
Findings from our meta-analysis are consistent with
those from prognostic studies in suggesting that base-
line ulcer area, ulcer duration, and recurrent ulceration
are independent predictors of time to healing.5-7
Although the effectiveness of the short stretch bandage
might be influenced by ankle joint mobility,1 we found
no significant interaction in our meta-analysis. Most
patients in the dataset (98%), however, were mobile.
Previous findings have indicated that the distinction
that enables prediction of healing is fixed versus non-
fixed joint.5
Strengths and weaknesses
Amajor strength of this research is the degree of rigour
using methods proposed by the Cochrane Collabora-
tion for conducting systematic reviews of interventions
and the Cochrane IPD Meta-analysis Methods
Group.8 9
All trials used non-blinded assessment of healing.
While it is not possible to define the direction or degree
of bias from this the potential for bias should not be
overlooked. We could not include two trials with una-
vailable data. These trials, however, accounted for less
than 10% of known randomised patients, and the
retrieval of around 90%means that the estimate gener-
ated can be viewed with confidence.
Conclusions
Findings suggest that patients with venous leg ulcers
treated with four layer bandages experience faster
healing than those treated with short stretch bandages.
Patients with larger ulcers, older ulcers, and recurrent
wounds have poorer healing prognosis regardless of
treatment. These data suggest that the observed benefits
are consistent despite differences in prognosis.Available
data from two trials did not suggest a difference in the
adverse event profiles of the two bandage types. Further
research is required on related outcomes such as ulcer
recurrence, change in ulcer area both as a predictor and
as an outcome, and cost effectiveness. Future trials
should incorporate blinded outcome assessment.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Venous leg ulceration is a common and recurring condition that imposes a considerable
burden on patients and healthcare providers
Compression treatment is the first line treatment, commonly applied as a four layer bandage
in the UK and short stretch bandage in other parts of the world
A systematic review of compression based on published trial reports did not detect a
difference between the two methods in terms of the number of patients healed at fixed time
points
WHAT THIS STUDY ADDS
When compared with the short stretch bandage, the four layer bandage increases the chance
of healing by around 30% when independent prognostic factors are taken into account
The benefit of the four layer bandage is consistent across patients with differing prognostic
profiles, independent predictors of delayed healing being larger baseline ulcer area, more
chronic ulceration, and previous ulceration
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Incidence of cervical cancer after several negative smear
results by age 50: prospective observational study
Matejka Rebolj,1 Marjolein van Ballegooijen,1 Elsebeth Lynge,2 Caspar Looman,1 Marie-Louise Essink-Bot,1
Rob Boer,1 Dik Habbema1
ABSTRACT
Objective To determine the incidence of cervical cancer
after several negative cervical smear tests at different
ages.
Design Prospective observational study of incidence of
cervical cancer after the third consecutive negative result
based on individual level data in a national registry of
histopathology and cytopathology (PALGA).
Setting Netherlands, national data.
Population 218 847 women aged 45-54 and 445 382
aged 30-44 at the time of the third negative smear test.
Main outcome measures 10 year cumulative incidence of
interval cervical cancer.
Results 105 women developed cervical cancer within
2 595964 woman years at risk after the third negative
result at age 30-44 and 42 within 1 278532 woman years
at risk after age 45-54. During follow-up, both age groups
had similar levels of screening. After 10 years of follow-
up, the cumulative incidence rate of cervical cancer was
similar: 41/100000 (95% confidence interval 33 to 51) in
the younger group and 36/100000 (24 to 52) in the older
group (P=0.48). The cumulative incidence rate of cervical
intraepithelial neoplasia grade I+ was twice as high in the
younger than in the older group (P<0.001).
Conclusions The risk for cervical cancer after several
negative smear results by age 50 is similar to the risk at
younger ages. Even after several negative smear results,
age is not a good discriminative factor for early cessation
of screening.
INTRODUCTION
The debate on early cessation of cervical cancer
screening forwomenwith several consecutive negative
smear results and no abnormalities by age 50 has been
ongoing for 15 years, with no clear conclusions in
terms of a change to guidelines. Several authors have
studied this issue by analysing the detection rates of
preinvasive cervical lesions in these women.1-9 In gen-
eral, they observed considerably lower detection rates
than in similarly screened younger women. On the
basis of this finding they argued that continued screen-
ing in this particular group of women is not as efficient
as screening among younger women and could be
stopped at the expense of only a limited increase in
the incidence of cervical cancer among these older
women.24 6 9 This could result in considerable savings
for the screening programmes. In the Netherlands it
would apply to about half of the women attending
screening around age 50.10
Because there is strong evidence that cervical intra-
epithelial neoplasia lesions have a higher probability of
progressing to invasive cancer in older women,11 12 a
lower detection rate after age 50 alone does not repre-
sent conclusive evidence for lower screening effi-
ciency. Data on invasive cancer have since become
available in a Dutch nationwide pathology registry
with screening histories linked to diagnostic histologi-
cal outcomes at the individual level. We measured the
incidence of invasive cancer after several consecutive
negative smear results in women around age 50 and in
younger women.
METHODS
Data
From the Dutch nationwide network and registry of
histopathology and cytopathology (PALGA), we
retrieved information on all cervix uteri cytological
and histological tests until 31 March 2004. The regis-
tration began in the late 1970s and achieved practically
complete coverage of pathology laboratories in 1990.13
The retrieved file contained data for all but one pathol-
ogy laboratory, accounting for less than 1% of smears
taken yearly. In the Netherlands, cervical cancer
screening became widespread after an extensive pilot
project that started in 1976. In 2003, 77% of women at
risk (that is, thosewith a cervix) between ages 30 and60
had had at least one smear in the preceding five years.14
In the network, women are identified through their
birth date and the first four letters of their family name
enabling linkage of the tests belonging to the same
woman. Because this code is not always unique, it
introduces anupwardbias in the incidence after a nega-
tive screen. To avoid this bias, we excluded women
with 0.5% of the most common first four letters of the
family name—that is, about 30% of women.
Final diagnoses for all non-cancer excerpts (all cytol-
ogy and non-cancer biopsies) were based on the
SNOMED oriented codes. We identified cases of cer-
vical cancer by checking the pathology reports for all
excerpts that included codes for cervical cancer for the
period 1994-2002.
Statistical analysis
We selected women in two age groups, 45-54 and
30-44 if they had a third consecutive negative primary
smear result in this age interval at any time since the
beginning of the registration. Women with previous
histological or cytological abnormalities were
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excluded. Women were followed up from the date of
the third negative smear until the date of the first diag-
nosis of cervical cancer or until the end of 2002,
whereas follow-up was left censored at the beginning
of 1994.
We first calculated the cumulative incidence rate of
cervical cancer in the period 1994-2002 by time since
the third negative result. For most women amaximum
of 10 years of follow-up was available. We tested the
difference in the rate between the age groups. Sec-
ondly, we tested the difference in the incidence rates
between the two age groups during the whole follow-
up period (the hazard rate). We tested time depen-
dency of relative hazards.
RESULTS
We identified 218 847 women in the older group and
445 382 in the younger group who met our inclusion
criteria. In the period between 1 January 1994 and 31
December 2002, 1.3 and 2.6 million person years in
follow-up accrued in these groups, respectively, an
average of 5.84 and 5.83 years per woman (table 1).
The two groups had a similar rate of screening after
the third negative smear: about a third had none,
about a third had one, and the remaining third had
more than one further primary test registered. Forty
two women in the older group and 105 women in the
younger group developed cervical cancer (table 1).
During follow-up, the difference in the cumulative
incidence rate between the age groups was never sig-
nificant (table 1). The average age of women was 37.
3 years in the younger group and 48.7 years in the
older group. The overall hazard ratio was 0.84 (95%
confidence interval 0.59 to 1.21) for the older com-
paredwith the younger group. The test for time depen-
dency of the relative hazards was non-significant
(P=0.86).
We calculated the cumulative incidence rate with
cervical intraepithelial neoplasia grade I+ as the end
point (table 2). By 10 years, the cumulative incidence
rate was 1258/100 000 (1209 to 1308) in the younger
group and 594/100 000 (547 to 645) in the older group.
The difference between both groups was significant
throughout the entire follow-up. The cumulative
incidence rate of cervical intraepithelial neoplasia
grade II+ was 721/100 000 (684 to 759) among
younger and 258/100 000 (227 to 293) among older
women. The cumulative incidence rate of cervical
intraepithelial neoplasia grade III+ was 445/100 000
Table 1 | Incidence of invasive cervical cancer after third consecutive negative smear result for two age groups
Age (years) at entry
Time (years) since third
negative smear
30-44 45-54
P value‡Woman years*
Women with invasive
cancer
Cumulative incidence
rate† (95% CI) Woman years*
Women with invasive
cancer
Cumulative incidence
rate† (95% CI)
≤1 324 512 4 1 (0 to 3) 172 920 3 2 (1 to 5) 0.66
>1-<3 628 471 16 6 (4 to 10) 344 825 16 11 (7 to 17) 0.09
≥5-<10 563 725 27 16 (12 to 21) 304 194 5 14 (10 to 21) 0.65
≥10-<15 837 359 43 41 (33 to 51) 378 075 13 36 (24 to 52) 0.48
≥15-<20 200 225 11 70 (51 to 95) 65 373 4 73 (39 to 135) 0.85
≥20 41 672 4 128 (79 to 207) 13 145 1 105 (50 to 219) 0.27
Total 2 595 964 105 — 1 278 532 42 — —
*Accrued between 1 January 1994 and 31 December 2002.
†Per 100 000 women.
‡Two sided, for difference in rate between two age groups at specific time points.
Table 2 | Incidence of cervical intraepithelial neoplasia I+ (CIN I+) after third consecutive negative smear result for two age groups
Age (years) at entry
Time (years) since third
negative smear
30-44 45-54
P value‡Woman years*
Women with
CIN I+
Cumulative incidence rate†
(95% CI) Woman years*
Women with
CIN I+
Cumulative incidence
rate† (95% CI)
≤1 324 381 233 72 (63 to 82) 172 850 90 52 (42 to 64) 0.008
>1-<3 627 524 584 258 (241 to 277) 344 441 172 152 (135 to 172) <0.001
≥5-<10 561 412 834 555 (529 to 583) 303 363 240 310 (284 to 339) <0.001
≥10-<15 829 336 1192 1258 (1209 to 1308) 375 786 224 594 (547 to 645) <0.001
≥15-<20 196 753 197 1707 (1622 to 1796) 64 635 30 769 (686 to 862) <0.001
≥20 40 898 24 1986 (1841 to 2143) 12 995 5 920 (772 to 1096) <0.001
Total 2 580 304 3064 — 1 274 070 761 — —
*Accrued between 1 January 1994 and 31 December 2002.
†Per 100 000 women.
‡Two sided for difference in rate between two age groups at specific time points.
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(417 to 476) among younger and 165/100 000 (140 to
194) among older women.
DISCUSSION
The relative risk of developing cervical cancer after a
third consecutive negative smear result amongwomen
around age 50 did not differ significantly from the risk
in younger women. This outcome was not biased by
differential screening during follow-up because there
was no difference between the age groups in this
respect. After several consecutive negative results the
screening efficiency in terms of detection and preven-
tion of cervical cancer is at the same level around age
50 as it is at younger ages.
In the analysed age groups (30-54 years), the inci-
dence rate of cervical cancer in the general population
was between10 and14 per 100 000womanyears in the
period 2001-5.15 Whether the relatively low incidence
rates observed in our well screened study groups war-
rant continued screening shouldbedeterminedby sub-
sequent analyses.
We observed a lower risk for cervical intraepithelial
neoplasia grades I+, II+, and III+ in the older group.
In this respect, our results are consistent with those of
others,2 4 6 and confirm that cervical intraepithelial neo-
plasia is not an accurate intermediate end point for the
question addressed.
Because we included women as soon as they had the
third consecutive negative result, younger women will
on average have been screened more intensely at a
younger age than women included in the older
group; the older women might therefore be at higher
risk. The selection criterion of being disease free on
three consecutive screenings, however, and the finding
that the screening attendance after the third negative
result was similar in both groups make such a bias
unlikely.
We selected women with negative screening his-
tories. In our data, inclusion of women with screen
detected abnormalities followed by three consecutive
primary negative results did not affect the two age
groups differently: the cumulative incidence rate at
10 years was 42 (30 to 57)/100 000 in the older group
and 42 (34 to 51)/100 000 in the younger group.
Implications of the study
The similarity in the cumulative incidence rate
between the two age groups is not unexpected given
the observed age specific incidence before screening
became widespread.16 In several Western European
countries, the incidence before screening rose rapidly
to a peak around ages 44-49 and declined thereafter.
Thus, whenwomen in the 30-44 year group are ageing,
they proceed from a lower to a higher risk age. The
opposite is true for women in the 45-54 year group.
This translates into roughly equal levels of cumulative
incidence rate for cancer during the first 10 years for
the two age groups.16
Our data do not permit a simple extension of our
study to older ages. For example, in 79 586 women
satisfying the criteria at ages 55-64, the 10 year cumu-
lative incidence rate was 47/100 000 (23 to 99) andwas
statistically comparable with that in women below age
55.Women aged 55 or older, however, had a consider-
ably lower screening intensity after the third negative
result. This diminishes the comparability with women
below that age.
The continued risk for cervical cancer is consistent
with the considerable rate of incident human papillo-
mavirus (HPV) infections throughout the age span we
focused on.17 18 As it is the screen detected cervical
intraepithelial neoplasia rather than an HPV infection
that can be treated, HPV screening instead of cytologi-
cal screening could eliminate relatively few extraHPV
infections before the age of 50. In case of HPV screen-
ing, our conclusions would therefore remain the same.
Conclusions
Using invasive cancer as the relevant end point our
conclusion that it would not be consistent to stop
screening women with several negative smear results
by age 50 while not also relaxing the screening policy
for younger women with similar screening histories
lends support to the current cervical cancer screening
guidelines in England and other developed
countries,19-23 which do not discriminate women by
age up to 60-65. Whether individual tailoring of
recommendations for further screening based on
screening histories would be an efficient alternative to
the current fixed schedule in any age group remains to
be explored.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
The detection of cervical intraepithelial neoplasia in
adequately screened women with several consecutive
negative smear results by age 50 is considerably lower than
among younger similarly screened women
The probability of progression of a cervical intraepithelial
neoplasia lesion to cervical cancer increases by age
WHAT THIS STUDY ADDS
The risk for cervical cancer after several negative smear
results by age 50 is similar to that at younger ages
It is therefore not consistent to stop screening women with
several consecutive negative smears after age 50
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Modifiable factors influencing relatives’ decision to offer
organ donation: systematic review
Arabella L Simpkin, Laura C Robertson, Vicki S Barber, J Duncan Young
ABSTRACT
Objective To identify modifiable factors that influence
relatives’ decision to allow organ donation.
Design Systematic review.
Data sourcesMedline, Embase, and CINAHL, without
language restriction, searched to April 2008.
Review methods Three authors independently assessed
the eligibility of the identified studies. We excluded
studies that examined only factors affecting consent that
could not be altered, such as donor ethnicity. We
extracted quantitative results to an electronic database.
For data synthesis, we summarised the results of studies
comparing similar themes.
ResultsWe included 20 observational studies and audits.
There were no randomised controlled trials. The main
factors associated with reduced rates of refusal were the
provision of adequate information on the process of organ
donation and its benefits; high quality of care of potential
organ donors; ensuring relatives had a clear
understanding of brain stem death; separating the
request for organ donation from notification that the
patient had died; making the request in a private setting;
and using trained and experienced individuals to make
the request.
Conclusions Limited evidence suggests that there are
modifiable factors in the process of requests for organ
donation, in particular the skills of the individual making
the request and the timing of this conversation, thatmight
have a significant impact on rates of consent. Targeting
these factors might have a greater and more immediate
effect on the number of organs for donation than
legislative or other long term strategies.
INTRODUCTION
The greatest identified impediment to organ donation
from patients after brain stem death on an intensive
care unit in theUK is refusal of consent by the relatives
of the donor.1-3 w2 A recent audit of all deaths in 341
intensive care units in the UK over a 33 month period
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showed that 41% of the relatives of potential organ
donors refused to consent to donation.4
Although the Human Tissue Act 2004,5 prioritises
the wishes of the potential donor over the relatives, it
is almost inconceivable that organs would be retrieved
from a brain stem dead patient against the wishes of his
or her family, so the consent of relatives will remain
important.
Interviews with the relatives of brain stem dead
patients have shown that about a third of those who
refused donation would not make the same decision
again,w3 whereas few consenting relatives regretted
their decision, suggesting thatmany decisions to refuse
to allow donation are not based on deeply held reli-
gious or other views. We reviewed published peer
reviewed studies to identify any modifiable factors in
the request for organ donation thatmight increase con-
sent rates.
METHODS
Searching—On 8 May 2008 we searched Medline,
Embase, and CINAHL. We used the search terms
“organ” or “tissue” and “don*” or “consent” without
language restrictions. We hand searched reference
lists of included studies.
Inclusion and exclusion criteria—We included studies
that reported modifiable factors associated with the
consent outcome of a request for organ donation to
the relatives of a beating heart potential organ donor
(a patientmeeting the criteria for brain stemdeath).We
included all studies containing data, whether from
observational or interventional studies.
Validity assessment and data abstraction—Three
authors screened the obtained titles and abstracts for
eligibility and obtained relevant full text articles.
Data synthesis—We reviewed papers to identify all
the modifiable factors associated with agreement or
refusal of consent. We report common themes in nar-
rative form under thematic headings.
RESULTS
Trial flow—Database searching produced a list of
22 032 publications. Of these, we excluded 21 786.
We reviewed 246 full papers. After we excluded 226
papers that did not meet the inclusion criteria, we
included 20 studies in the review.w1-w20
Study characteristics—The studies identified were of
two types. In observational studies the proportion of
successful requests for organ donation was determined
when the factor was present and compared with the
proportionwhen itwas not. In “before and after” audits
the factor was modified and the effect on subsequent
organ donation noted. We did not identify any rando-
mised controlled trials.
Data synthesis—We identified modifiable factors that
apparently influence relatives’decisions to alloworgan
donation into six categories: information discussed
during the request; perceived quality of care of the
donor; understanding of brain stemdeath; specific tim-
ing of the request; setting in which the request is made;
and approach and expertise of the individual making
the request.We present all the modifiable factors iden-
tified in studieswith a P value of≤0.05 for differences in
the proportion of relatives giving consent to organ
donation with the factor present or absent. We also
present modifiable factors for which no statistical
results were reported butwhich the authors considered
relevant.
Information discussed during request—Five studies retro-
spectively collected data via chart reviews and inter-
views with staff and families in an attempt to establish
whether information provided during the request pro-
cess was associated with the family’s decision to donate
or not donate organs for transplantation.w1 w3 w5 w18 w20
Siminoff et al studied 420 donor eligible patients.w1 w20
Factors correlating with consent to organ donation
were delivery of information on the costs of donation;
the impact of donation on funeral arrangements; and
assurances that the family had a choice about which
organs to donate. When healthcare professionals men-
tioned that donation had the potential to help others,
families were also more likely to donate, but telling
families that they were required to ask about donation
had a negative impact on consent rates.w1 The other
papers showed a significantly higher rate of consent
when families thought they had been given enough
information to make an informed decision about organ
donation.w3 w5 w18 w20
Perceived quality of care of donor—Perceived quality of
care during the hospital stay had a significant impact on
consent rates in the threepapers that examined this.w1 w3 w4
All threepapers showed that anegativeperceptionof care
results in a decreased rate of consent.
Understanding of brain stem death—In five papers there
was a significant association between understanding
and consent to organ donation,w1 w3-w6 with a sixth
paper showing a non-significant increase in consent
in families who understand brain stem death but a sig-
nificant difference in consent rates in families accepting
the concept of brain stem death.w19 In a review of 285
families, 71% that had complete knowledge of brain
stem death agreed to donation compared with only
29% of those with incomplete or inaccurate knowledge
of brain stemdeath.w4When familieswere asked if they
agreed that people cannot recover when they are brain
dead, 80% of donor family respondents correctly
agreed with this statement, while only 48% of the
non-donor family group did so.w3
Timing of the request—A series of nine reports all sug-
gested that there is an improved rate of consent when
there is temporal separation (“decoupling”) between
notification and acceptance of brain stem death and
request for donation.w1-w4 w7-w9 w14 w18 The most impor-
tant factor seems to be that the request for donation
does not occur at the same time as the notification of
death or testing for brain stem death.Niles andMattice
determined that the consent rate was similar regardless
of whether families were approached either before
(62%) or after (57%) death butmuch lower when dona-
tionwasmentioned at the time of the death notification
(25%).w9 Giving families enough time to make a
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decision was also important.w1 w3 w4 w18 In a study that
retrospectively interviewed the next of kin of 164
potential organ donors, 83% of donor and 56% of
non-donor family respondents said that they were
given enough time to understand that their relative
was dead before medical staff brought up organ dona-
tion.w3
Setting in which the request is made—Evidence that a
private location for discussion about organ donation
improves consent rates is clearly documented.w2 w3 In
two studies consent rates for requests made in settings
that provided little privacy (requests made by tele-
phone, in the patient’s room, at the nursing station, or
in the hallway) were 45% and 30% comparedwith con-
sent rates of 56% and 52% inmore private settings.w2 w3
One study showed no significant benefit of a private
setting for organ donation requests.w20
Approach and expertise of the person making the request—
The most studied factor influencing consent is the
approach and expertise of the person making the
request. Fourteen studies investigated this.w1-w5 w7 w10-w17
Differences in consent rates seem to be associated with
which professionals are involved with the request pro-
cess.w1 w2 w4 w7 w10 w11 In a study of 707 requests for organ
donation, a combined approach by hospital staff and
coordinators from an organ procurement organisation
(OPO) resulted in a consent rate of 72%. Hospital staff
alone had a consent rate 53%, while coordinators alone
had a consent rate 62%.w2 Families have reported that
conversations withOPO staff were crucial to their dona-
tion decision. Talking to a member of OPO staff before
being asked tomake a decision and spendingmore time
with a member of OPO staff were both strongly asso-
ciated with donation.w1There is a correlation between
staff training in effective procedures for requesting
organ donation and donation rates.w14-w16 In hospitals
with high rates of organ donation, 53% of the staff had
received training comparedwith 24%of staff in hospitals
with low rates of organ donation.w14 Finally, it seems that
courtesy increases organ donation rates.w5
DISCUSSION
The main modifiable factors significantly associated
with whether relatives deny or allow organ donation
were information discussed during the request, per-
ceived quality of care of the donor, understanding of
brain stem death, specific timing of the request, setting
in which the request is made, and the approach and
skill of the individual making the request. Ensuring
that adequate time is available both tomake the request
and to allow families to consider the request also seems
important.
Limitations and strengths
Our review will identify only those factors that have
been studied and reported and only those at the level
of individual requests. Factors modifiable at a popula-
tion level, such as the fraction of the population parti-
cipating in an organ donor register, and some factors
modifiable at a hospital level, such as local donation
champions, did not appear in the identified studies.
Many of the studies identified were retrospective
reviews of medical records. There was a large reliance
on hospital or OPO staff as data collectors, who might
not be unbiased observers. Most of the studies were
based on small numbers, and there were no rando-
mised controlled studies fromwhich to draw data. Sev-
eral of the studies were based on structured interviews
with donor and non-donor families, with little detail on
whether the sample interviewed are representative of
the whole. These interviews were based on family
recollections and thus are accurate only to the extent
that their memories of these events are accurate, intro-
ducing recall bias. Finally, as the studies are observa-
tional, factors correlated with consent to organ
donation might not be causative.
The two factors that had the largest effect on consent
rates were the person making the request and the tim-
ing of this conversation. Consent rates were higher
when the request was made by the organ procurement
coordinator (donor transplant coordinator in the UK)
in conjunction with hospital staff members. Clearly, it
is not possible to place a dedicated donor transplant
coordinator in every hospital, but it might be possible
to consider this in hospitals with larger numbers of
potential organ donors. UK Transplant, which pro-
vides support to transplant services in the UK, has
adopted this strategy.
There is a need for large rigorously conducted inter-
vention studies to test the factors that might be modi-
fied to increase organ donation.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
There is a severe shortage of organs for transplantation
The largest impediment to organ procurement is relatives’ refusal
WHAT THIS STUDY ADDS
The timing of the request and the person making the request have a significant impact on
consent rates
Modifying the consent request process might be the fastest way to increase organ donation
rates
These changes could be implemented without undue delay in the UK
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